CO COHANCE
Cohance Lifesciences Q1 2026
COCOHANCE

Cohance Lifesciences Q1 FY26 results (Apr–Jun 2025) and concall

Healthcare · Concall AI · Call held 13 Aug 2025

Management summary

  • Cohance Lifesciences delivered a resilient Q1 FY26, marking its first full quarter as a unified platform.
  • While reported CDMO growth was muted by inventory de-stocking in two large commercial molecules, the underlying business showed robust momentum, particularly in niche modalities like ADCs and Oligonucleotides.
  • Management is aggressively investing in global capacity and leadership to hit its ambitious 2030 growth targets.

Source: Inve concall analysis and management guidance record.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26
Revenue676 840 549
EBITDA237 229 112
Net profit153 117 46
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • Total Revenue Revenue · by 2030 · High confidence $1 billion (₹85 billion)

Margin

  • EBITDA Margin Margin · medium term · Medium confidence mid-30s

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct, 1 evasive
Organic vs Inorganic Growth for FY26 Evasive
For us, the organic and inorganic are two sides of the same coin. It is about capital allocation... I would urge you guys to kind of think about it in the way we look at and not separating it as an organic or inorganic.

Management declined to provide a specific organic growth target for the current fiscal year, focusing instead on their M&A-led strategy.

Asked by Shyam Srinivasan

US Tariff Exposure and Supply Chain Direct
Most of our current agreements with the customers are on FOB basis. We do not have the liability to pay the tariffs, when the goods reach the shore of U.S.

Clarifies that the company has minimal financial exposure to potential US trade tariffs due to contract structures and product classification (intermediates vs APIs).

Asked by Avnish Burman

Unlock risks & concerns, Q2 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 3 risks, concerns & management red flags
  • Watchlist triggers for Q2 FY26
  • +3 more guidance targets & verbatim management quotes
  • +1 more analyst Q&A exchange & evasion checks
  • Full section-by-section call narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image